Avadel Pharmaceuticals (AVDL) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Avadel Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$27.96M

Latest Revenue (Q)

$50.02M

Main Segment (Y)

Vazculep

Main Geography (Y)

UNITED STATES

Avadel Pharmaceuticals Revenue by Period

Avadel Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$27.96M	100.00%
2022-12-31	-	100.00%
2021-12-31	-	-100.00%
2020-12-31	$22.33M	-62.28%
2019-12-31	$59.22M	-42.66%
2018-12-31	$103.27M	-40.22%
2017-12-31	$172.74M	14.97%
2016-12-31	$150.25M	-13.26%
2015-12-31	$173.21M	1072.31%
2014-12-31	$14.78M	-34.17%
2013-12-31	$22.44M	-14.01%
2012-12-31	$26.10M	-19.94%
2011-12-31	$32.60M	-12.12%
2010-12-31	$37.09M	-11.93%
2009-12-31	$42.12M	9.06%
2008-12-31	$38.62M	5.36%
2007-12-31	$36.65M	59.23%
2006-12-31	$23.02M	-2.45%
2005-12-31	$23.60M	-57.41%
2004-12-31	$55.41M	120.17%
2003-12-31	$25.17M	36.73%
2002-12-31	$18.41M	40.64%
2001-12-31	$13.09M	20.04%
2000-12-31	$10.90M	-1.25%
1999-12-31	$11.04M	15.94%
1998-12-31	$9.52M	17.56%
1997-12-31	$8.10M	65.31%
1996-12-31	$4.90M	-

Avadel Pharmaceuticals generated $27.96M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 27.08% compared to the same period a year ago.

Avadel Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$50.02M	20.53%
2024-06-30	$41.50M	52.71%
2024-03-31	$27.18M	39.71%
2023-12-31	$19.45M	177.35%
2023-09-30	$7.01M	368.85%
2023-06-30	$1.50M	100.00%
2023-03-31	-	100.00%
2022-12-31	-	100.00%
2022-09-30	-	100.00%
2022-06-30	-	100.00%
2022-03-31	-	100.00%
2021-12-31	-	100.00%
2021-09-30	-	100.00%
2021-06-30	-	100.00%
2021-03-31	-	100.00%
2020-12-31	-	-100.00%
2020-09-30	$14.23M	41.01%
2020-06-30	$10.09M	-17.58%
2020-03-31	$12.24M	11.35%
2019-12-31	$10.99M	-22.73%
2019-09-30	$14.23M	-18.94%
2019-06-30	$17.55M	6.80%
2019-03-31	$16.44M	-21.43%
2018-12-31	$20.92M	5.52%
2018-09-30	$19.83M	-32.17%
2018-06-30	$29.23M	-12.20%
2018-03-31	$33.29M	-2.79%
2017-12-31	$34.25M	-13.68%
2017-09-30	$39.67M	-14.33%
2017-06-30	$46.31M	-11.80%
2017-03-31	$52.51M	21.87%
2016-12-31	$43.09M	34.28%
2016-09-30	$32.09M	-17.42%
2016-06-30	$38.86M	7.30%
2016-03-31	$36.22M	-16.49%
2015-12-31	$43.37M	-8.35%
2015-09-30	$47.32M	-4.97%
2015-06-30	$49.80M	52.16%
2015-03-31	$32.73M	-444.12%
2014-12-31	$-9.51M	-235.32%
2014-09-30	$7.03M	-13.04%
2014-06-30	$8.08M	-11.91%
2014-03-31	$9.18M	48.49%
2013-12-31	$6.18M	10.68%
2013-09-30	$5.58M	0.76%
2013-06-30	$5.54M	7.80%
2013-03-31	$5.14M	-29.69%
2012-12-31	$7.31M	35.42%
2012-09-30	$5.40M	-10.53%
2012-06-30	$6.03M	-18.03%
2012-03-31	$7.36M	-14.90%
2011-12-31	$8.65M	-17.11%
2011-09-30	$10.43M	54.51%
2011-06-30	$6.75M	-0.16%
2011-03-31	$6.76M	-49.71%
2010-12-31	$13.45M	67.28%
2010-09-30	$8.04M	7.00%
2010-06-30	$7.51M	-7.07%
2010-03-31	$8.09M	-23.64%
2009-12-31	$10.59M	7.00%
2009-09-30	$9.90M	3.37%
2009-06-30	$9.57M	-20.57%
2009-03-31	$12.05M	27.34%
2008-12-31	$9.47M	3.62%
2008-09-30	$9.13M	-0.20%
2008-06-30	$9.15M	-15.76%
2008-03-31	$10.87M	2.88%
2007-12-31	$10.56M	-

Avadel Pharmaceuticals generated $50.02M in revenue during Q3 2024, up 20.53% compared to the previous quarter, and up 3343.92% compared to the same period a year ago.

Avadel Pharmaceuticals Revenue Breakdown

Avadel Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 20
Vazculep	$10.43M
Other Products	$159.00K
Bloxiverz	$2.20M
License	-
Akovaz	$9.54M

Avadel Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 20: Vazculep (46.70%), Akovaz (42.74%), Bloxiverz (9.85%), and Other Products (0.71%).

Quarterly Revenue by Product

Product/Service	Jun 20	Mar 20	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18
Vazculep	$4.92M	$5.51M	$8.79M	$9.41M	$9.47M	$8.76M	$11.38M	$12.96M
Other Products	$180.00K	$-21.00K	$-231.00K	$-160.00K	$604.00K	$373.00K	$31.00K	$1.83M
Bloxiverz	$800.00K	$1.40M	$1.47M	$2.36M	$2.57M	$3.66M	$5.54M	$7.49M
Akovaz	$4.20M	$5.35M	$4.21M	$5.95M	$3.79M	$5.99M	$11.88M	$10.22M
Product	-	-	$14.23M	$17.55M	$16.44M	$19.83M	-	-
License	-	-	-	-	-	-	-	-
Noctiva	-	-	-	-	-	$1.05M	$289.00K	$666.00K

Avadel Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 20: Vazculep (48.71%), Akovaz (41.58%), Bloxiverz (7.93%), and Other Products (1.78%).

Avadel Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 20
IRELAND	-
UNITED STATES	$22.33M

Avadel Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: UNITED STATES (100.00%).

Avadel Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AMRX	Amneal Pharmaceuticals	$2.39B	$702.47M
NBIX	Neurocrine Biosciences	$1.89B	$622.10M
ALKS	Alkermes	$1.66B	$378.14M
ANIP	ANI Pharmaceuticals	$486.82M	$148.33M
ITCI	Intra-Cellular Therapies	$462.18M	$175.38M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
EGRX	Eagle Pharmaceuticals	$316.61M	$64.65M
DVAX	Dynavax	$232.28M	$79.34M
DCPH	Deciphera Pharmaceuticals	$163.36M	$45.00M
ASRT	Assertio	$152.07M	$29.20M
LFCR	Lifecore Biomedical	$128.26M	$24.70M
DERM	Journey Medical	$79.18M	$14.86M
AQST	Aquestive Therapeutics	$50.58M	$13.54M
AVDL	Avadel Pharmaceuticals	$27.96M	$50.02M
AGRX	Agile Therapeutics	$19.59M	$5.58M
JUPW	Safety Shot	$6.20M	$910.01K
EVOK	Evoke Pharma	$5.18M	$2.65M
ACRX	Talphera	$651.00K	$117.00K

AVDL Revenue FAQ

What is Avadel Pharmaceuticals’s yearly revenue?

Avadel Pharmaceuticals's yearly revenue for 2023 was $27.96M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. AVDL's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.

What is Avadel Pharmaceuticals’s quarterly revenue?

Avadel Pharmaceuticals's quarterly revenue for Q3 2024 was $50.02M, a 20.53% increase from the previous quarter (Q2 2024), and a 613.22% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $41.5M, a 52.71% increase from the previous quarter (Q1 2024), and a 2674.33% increase year-over-year (Q2 2023). AVDL's quarterly revenue for Q1 2024 was $27.18M, a 39.71% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Avadel Pharmaceuticals’s revenue growth rate?

Avadel Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -52.78%.

What are Avadel Pharmaceuticals’s revenue streams?

Avadel Pharmaceuticals's revenue streams in c 20 are Vazculep, Other Products, Bloxiverz, and Akovaz. Vazculep generated $10.43M in revenue, accounting 46.70% of the company's total revenue Other Products generated $159K in revenue, accounting 0.71% of the company's total revenue Bloxiverz generated $2.2M in revenue, accounting 9.85% of the company's total revenue Akovaz generated $9.54M in revenue, accounting 42.74% of the company's total revenue

What is Avadel Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 20, the largest source of revenue of Avadel Pharmaceuticals was Vazculep. This segment made a revenue of $10.43M, representing 46.70% of the company's total revenue.